Piper Sandler Maintains Overweight on Replimune Group, Raises Price Target to $27
Benzinga Newsdesk 4 days ago
Analyst RatingsNewsPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Piper Sandler analyst Allison Bratzel maintains Replimune Group (NASDAQ:REPL) with a Overweight and raises the price target from $14 to $27.
Piper Sandler analyst Allison Bratzel maintains Replimune Group (NASDAQ:REPL) with a Overweight and raises the price target from $14 to $27.
